RAFT polymerzation for delivery of bioactives

J. Chiefari, C. Guerrero-Sanchez, G. Moad, S. H. Thang, J. Tsanaktsidis, Thilak Gunatillake, T. Hinton, S. Shi, M. Tizard

Research output: Chapter in Book/Report/Conference proceedingConference PaperResearch


This paper describes recent efforts on the use of Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerization for synthesis of well-defined polymer conjugates for delivery of bioactives. The research is illustrated by work on with the antitumor drug SN38, to improve water solubility and cell viability, and the delivery of siRNA, for gene silencing. The RAFT polymers are conjugated to the active through a covalent linkage, in the case of anticancer drug SN38, and by ionic association, for the case of siRNA. Preliminary results are extremely encouraging. The synthesized RAFT ABA triblock polymers provided 100% siRNA uptake and gave gene silencing similar to that of the transfection reagent Lipofectamine™. In both examples RAFT-acive conjugates polymers were well-tolerated showing no discernable cell cytotoxicity.
Original languageEnglish
Title of host publicationTechnical Proceedings of the 2011 NSTI Nanotechnology Conference and Expo, NSTI-Nanotech 2011
Subtitle of host publicationBoston, MA, United States; 13-16 June 2011
Number of pages3
Publication statusPublished - 23 Nov 2011
Externally publishedYes


  • Bioconjuates
  • RAFT polymerization
  • siRNA
  • SN38 antitumor drug

Cite this